SLC5A2 and diabetes mellitus: SGLT2 inhibitors (SGLT2‐I) are a class of antidiabetic drugs that demonstrated unexpectedly beneficial effects in HF during the EMPA‐Reg trial in diabetes management (Zinman et al, 2015).